Introduction/Background Clear cell carcinoma (CCC) comprises a rare yet an aggressive subtype, accounting for less than 5% of all uterine carcinomas. Treatment programs of CCC endometrium at different stages varies yet outcome of this tumor has not improved.

Methodology This study presents a single institution experience regarding the clinicopathological features, treatment strategies outcomes used in CCC endometrium and discuss parameters associated with Recurrence free survival (RFS) and Overall survival (OS).

25 Patients of Endometrial CCC, diagnosed and treated between 2011 and 2018, were reviewed retrospectively. All data related to patient‘s demographic, clinical, histopathology assessment, adjuvant and survival outcomes was evaluated. RFS, OS were estimated as well as prognostic factors associated with OS were analyzed using Kaplan -Meir’s, Cox regression analysis

Results The median follow- up time was 28 months, and the mean age at diagnosis was 59.8 years. There were 18 (72%) patients with pure clear cell carcinoma and 7(28%) with mixed histology.

The majority were early stage [FIGO IA n=7 [28%], IB- n=3[12%], FIGO II n=4[16%], FIGO III n=6 [24%], FIGO IV n=5[20%].

18 (72%) Patients received adjuvant platinum and taxane based chemotherapy with or without radiotherapy in the form of EBRT and/or vaginal brachytherapy. 5(20%) patients received Palliative chemotherapy only.

6 (24%) patients died during follow up, 6(24%) develop recurrence (local-1, distant-5). The Mean OFS, RFS were 62.98 and 55.83 months respectively.

The OS was significantly shorter in patients with >2 cm size tumour, cervical, adenexal invasion, lymph node metastasis and thus with advanced stage disease.

Conclusion Patient with early stage UCCC had an excellent outcomes. The use of combined treatment approach is better and it is reasonable to offer the chemotherapy in early stage although its true benefit in stage I are still up for discussion.

Disclosure Nothing to disclose.